OPRX: Q3 Revenue Sets New Record, Up 202%

Zacks Small Cap Research

By Brian Marckx, CFA

Q3 2013 Pre-announcement:
  Revenue Up 202% yoy and 14% Ahead of Our Estimate...

Yesterday (10/8/13) OptimizeRx (OPRX) pre-announced expected revenue for the third quarter ending 9/30/13.  The company expects revenue of $1.37 million, which will be an increase of 202% from the same period in 2012 and is 14% better than our estimated $1.20 million.  The Q3 revenue number will also crush the previous quarterly record of $1.10 million, set in Q2 of this year.  The company also disclosed that there were almost 325k coupons distributed via SampleMD in the quarter, an increase of 22% from Q2 2013 and +260% from Q3 2012.

We have updated our model for the pre-announcement.  We now look for full-year 2013 revenue of $4.8 million (+133% yoy), up from $4.3 million prior to the announcement.  Our current year EPS estimate has moved from $0.04 to $0.05.  We have also made some slight upward adjustments to our out-year revenue estimates given the moderately steeper recent ramp in growth relative to our expectations.  We are maintaining our Outperform rating and $3.50/share price target. 

A copy of the latest research report can be downloaded here >> 
 OptimizeRx Report

Please visit 
SCR.Zacks.com for additional information on our research and coverage universe, and Subscribe to receive our articles and reports emailed directly to you each morning.

View Comments (0)